IMPORTANCE: Because treatment for oropharyngeal squamous cell carcinoma (OPSCC), especially in patients of older age, is associated with decreased patient quality of life (QOL) after surgery, demonstration of a less QOL-impairing treatment technique would improve patient satisfaction substantially. OBJECTIVE: To determine swallowing, speech, and QOL outcomes following transoral robotic surgery (TORS) for OPSCC. DESIGN, PARTICIPANTS, AND SETTING: This prospective cohort study of 81 patients with previously untreated OPSCC was conducted at a tertiary care academic comprehensive cancer center. INTERVENTIONS: Primary surgical resection via TORS and neck dissection as indicated. MAIN OUTCOMES AND MEASURES: Patients were asked to complete the Head and Neck Cancer Inventory (HNCI) preoperatively and at 3 weeks as well as 3, 6, and 12 months postoperatively. Swallowing ability was assessed by independence from a gastrostomy tube (G-tube). Clinicopathologic and follow-up data were also collected. RESULTS: Mean follow-up time was 22.7 months. The HNCI response rates at 3 weeks and 3, 6, and 12 months were 79%, 60%, 63%, and 67% respectively. There were overall declines in speech, eating, aesthetic, social, and overall QOL domains in the early postoperative periods. However, at 1 year post TORS, scores for aesthetic, social, and overall QOL remained high. Radiation therapy was negatively correlated with multiple QOL domains (P < .05 for all comparisons), while age older than 55 years correlated with lower speech and aesthetic scores (P < .05 for both). Human papillomavirus status did not correlate with any QOL domain. G-tube rates at 6 and 12 months were 24% and 9%, respectively. Greater extent of TORS (>1 oropharyngeal site resected) and age older than 55 years predicted the need for a G-tube at any point after TORS (P < .05 for both). CONCLUSIONS AND RELEVANCE: Patients with OPSCC treated with TORS maintain a high QOL at 1 year after surgery. Adjuvant treatment and older age tend to decrease QOL. Patients meeting these criteria should be counseled appropriately.
IMPORTANCE: Because treatment for oropharyngeal squamous cell carcinoma (OPSCC), especially in patients of older age, is associated with decreased patient quality of life (QOL) after surgery, demonstration of a less QOL-impairing treatment technique would improve patient satisfaction substantially. OBJECTIVE: To determine swallowing, speech, and QOL outcomes following transoral robotic surgery (TORS) for OPSCC. DESIGN, PARTICIPANTS, AND SETTING: This prospective cohort study of 81 patients with previously untreated OPSCC was conducted at a tertiary care academic comprehensive cancer center. INTERVENTIONS: Primary surgical resection via TORS and neck dissection as indicated. MAIN OUTCOMES AND MEASURES: Patients were asked to complete the Head and Neck Cancer Inventory (HNCI) preoperatively and at 3 weeks as well as 3, 6, and 12 months postoperatively. Swallowing ability was assessed by independence from a gastrostomy tube (G-tube). Clinicopathologic and follow-up data were also collected. RESULTS: Mean follow-up time was 22.7 months. The HNCI response rates at 3 weeks and 3, 6, and 12 months were 79%, 60%, 63%, and 67% respectively. There were overall declines in speech, eating, aesthetic, social, and overall QOL domains in the early postoperative periods. However, at 1 year post TORS, scores for aesthetic, social, and overall QOL remained high. Radiation therapy was negatively correlated with multiple QOL domains (P < .05 for all comparisons), while age older than 55 years correlated with lower speech and aesthetic scores (P < .05 for both). Human papillomavirus status did not correlate with any QOL domain. G-tube rates at 6 and 12 months were 24% and 9%, respectively. Greater extent of TORS (>1 oropharyngeal site resected) and age older than 55 years predicted the need for a G-tube at any point after TORS (P < .05 for both). CONCLUSIONS AND RELEVANCE: Patients with OPSCC treated with TORS maintain a high QOL at 1 year after surgery. Adjuvant treatment and older age tend to decrease QOL. Patients meeting these criteria should be counseled appropriately.
Authors: Gregory S Weinstein; Bert W O'Malley; J Scott Magnuson; William R Carroll; Kerry D Olsen; Lixia Daio; Eric J Moore; F Christopher Holsinger Journal: Laryngoscope Date: 2012-07-02 Impact factor: 3.325
Authors: Yogesh I More; Terance T Tsue; Douglas A Girod; John Harbison; Kevin J Sykes; Carson Williams; Yelizaveta Shnayder Journal: JAMA Otolaryngol Head Neck Surg Date: 2013-01 Impact factor: 6.223
Authors: Martina A Broglie; Alex Soltermann; Sarah R Haile; Christof Röösli; Gerhard F Huber; Stephan Schmid; Sandro J Stoeckli Journal: Laryngoscope Date: 2012-11-14 Impact factor: 3.325
Authors: Inge M Oskam; Irma M Verdonck-de Leeuw; Neil K Aaronson; Birgit I Witte; Remco de Bree; Patricia Doornaert; Johannes A Langendijk; C René Leemans Journal: Oral Oncol Date: 2013-01-11 Impact factor: 5.337
Authors: Abrahim Al-Mamgani; Peter van Rooij; Lisa Tans; Gerda M Verduijn; Aniel Sewnaik; Rob J Baatenburg de Jong Journal: Radiother Oncol Date: 2013-02-08 Impact factor: 6.280
Authors: Ozlem E Tulunay-Ugur; Christopher McClinton; Zachary Young; Jose A Penagaricano; Anne-Marie Maddox; Emre Vural Journal: Otolaryngol Head Neck Surg Date: 2012-09-05 Impact factor: 3.497
Authors: Peter T Dziegielewski; Michael L Ho; Jana Rieger; Prabhjyot Singh; Morgan Langille; Jeffrey R Harris; Hadi Seikaly Journal: Laryngoscope Date: 2012-09-05 Impact factor: 3.325
Authors: Martin Canis; Alexios Martin; Martina Kron; Alexandra Konstantinou; Friedrich Ihler; Hendrik A Wolff; Christoph Matthias; Wolfgang Steiner Journal: Eur Arch Otorhinolaryngol Date: 2012-12-29 Impact factor: 2.503
Authors: Arun Sharma; Sapna Patel; Fred M Baik; Grant Mathison; Brendan H G Pierce; Samir S Khariwala; Bevan Yueh; Stephen M Schwartz; Eduardo Méndez Journal: JAMA Otolaryngol Head Neck Surg Date: 2016-07-01 Impact factor: 6.223